Tevogen Bio (NASDAQ:TVGNW – Get Free Report) is expected to issue its results before the market opens on Thursday, August 13th. Analysts expect Tevogen Bio to announce earnings of ($2.5350) per share for the quarter.
Tevogen Bio Price Performance
TVGNW stock opened at $0.05 on Thursday. The firm has a 50 day simple moving average of $0.05 and a two-hundred day simple moving average of $0.04. Tevogen Bio has a one year low of $0.03 and a one year high of $0.08.
About Tevogen Bio
Tevogen Bio is a clinical-stage biotechnology company focused on developing allogeneic T cell receptor (TCR)-based immunotherapies for the treatment of cancer and infectious diseases. Leveraging a proprietary platform of engineered T cells, the company aims to deliver off-the-shelf cellular products that can recognize and eliminate disease-specific antigens without the need for patient-matched cell manufacturing.
The company’s pipeline encompasses programs targeting chronic viral infections, including hepatitis B virus and SARS-CoV-2, as well as cytomegalovirus, alongside oncology indications such as solid and hematological tumors.
Featured Stories
- Five stocks we like better than Tevogen Bio
- SpaceX: Love the Company, But the Stock Is a Harder Call
- Ulta’s Growth Is Real, But So Are the Risks
- BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
- Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth
Receive News & Ratings for Tevogen Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tevogen Bio and related companies with MarketBeat.com's FREE daily email newsletter.
